A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis
Status:
Terminated
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety and efficacy of OPC-6535 (tetomilast) and
to determine its optimal dose by once-daily oral administration at 0, 12.5, 25, or 50 mg for
8 weeks in combination with a fixed oral dose of 5-aminosalicylic acid (5-ASA) in patients
with active ulcerative colitis.